Starbucks’ Q3 Earnings ROSE 19% and 4 Hot Stocks Attracting Investor Attention
MetroPCS Communications Inc (NYSE:PCS): After the company’s financial and operational results were released for the quarter ending, June 30, 2012, shares of MetroPCS Communications Inc., went up from $2.31 (or 36.78%) to $8.59, in U.S. currency. Total revenues for the second quarter were approximately $1.3 billion, which is an increase of 6% from the prior year’s quarter. MetroPCS also showed a net income of $149 million, or an increase of 77% year-over-year. There were 32.65 million stock shares traded, which was 5.6 times more than an average volume. Insiderslab.com has suggested that insider transactions can greatly influence investment decisions. In addition, academic studies have indicated that company insiders traditionally make higher investment returns than ordinary investors. Shares of MetroPCS Communications Inc. are trading at 4.66% higher today.
Don’t Miss: Amazon Has BIG Plans for Kindle Fire.
Starbucks Corporation (NASDAQ:SBUX): Starbucks Corporation’s (NASDAQ:SBUX) fiscal third-quarter earnings rose 19%, but the coffee giant said that it saw slowing, same store sales growth in June and has, therefore, lowered their earnings guidance going forward. Earnings missed the company’s estimates, and marked the first time that Starbucks fell short of analysts’ expectations, since the quarter ended, December 2008. Pre-market shares fell 10% to $47.10. Shares of Starbucks Corp. are trading at 10.07% lower today. A competitor of Starbucks,Caribou Coffee Co.’s (NASDAQ:CBOU) stocks also fell 4.34% to $11.45.
Amazon.com, Inc. (NASDAQ:AMZN): After reinvesting in the business, Amazon.com posted a sharp drop in their second quarter profit, as expected. The Internet retailer reported a razor-thin $7 million profit, or a penny a share, down from $191 million a year ago. Sales rose 29 percent to $12.83 billion. Shares of Amazon.com, Inc. are trading at 6.95% higher today.
Amarin Corporation plc (NASDAQ:AMRN): U.S. approval for Amarin Corp. (NASDAQ:AMRN)’s first product, a drug to combat high levels of blood fat that can lead to stroke and heart attack, included limits on its use. This may have disappointed investors. Unfortunately, even after yesterday’s increase, Amarin’s American depositary receipts fell. Jon Lecroy, an MKM Partners analyst in Stamford, Connecticut, believes that this decline, where investors are selling after they hear the news of a drug’s approval, has been a continuing trend. He also mentioned that the drug’s label may not have been as broad as some investors were expecting. Shares of Amarin Corporation PLC, are trading at 9.44% lower today.